Author:
Kawasaki Makiri,Al-Shama Rushd F. M.,Nariswari Fransisca A.,Fabrizi Benedetta,van den Berg Nicoline W. E.,Wesselink Robin,Neefs Jolien,Meulendijks Eva R.,Baalman Sarah W. E.,Driessen Antoine H. G.,de Groot Joris R.
Abstract
AbstractAtrial fibrosis serves as an arrhythmogenic substrate in atrial fibrillation (AF) and contributes to AF persistence. Treating atrial fibrosis is challenging because atrial fibroblast activity is multifactorial. We hypothesized that the primary cilium regulates the profibrotic response of AF atrial fibroblasts, and explored therapeutic potentials of targeting primary cilia to treat fibrosis in AF. We included 25 patients without AF (non-AF) and 26 persistent AF patients (AF). Immunohistochemistry using a subset of the patients (non-AF: n = 10, AF: n = 10) showed less ciliated fibroblasts in AF versus non-AF. Acetylated α-tubulin protein levels were decreased in AF, while the gene expressions of AURKA and NEDD9 were highly increased in AF patients’ left atrium. Loss of primary cilia in human atrial fibroblasts through IFT88 knockdown enhanced expression of ECM genes, including FN1 and COL1A1. Remarkably, restoration or elongation of primary cilia by an AURKA selective inhibitor or lithium chloride, respectively, prevented the increased expression of ECM genes induced by different profibrotic cytokines in atrial fibroblasts of AF patients. Our data reveal a novel mechanism underlying fibrotic substrate formation via primary cilia loss in AF atrial fibroblasts and suggest a therapeutic potential for abrogating atrial fibrosis by restoring primary cilia.
Publisher
Springer Science and Business Media LLC
Reference80 articles.
1. Wolf, P. A., Abbott, R. D. & Kannel, W. B. Atrial fibrillation as an independent risk factor for stroke: The Framingham study. Stroke 22, 983–988 (2018).
2. Wolf, P. A., Dawber, T. R., Thomas, H. E. & Kannel, W. B. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: The Framingham study. Neurology 28, 973–977 (1978).
3. Anter, E., Jessup, M. & Callans, D. J. Atrial fibrillation and heart failure: Treatment considerations for a dual epidemic. Circulation 119, 2516–2525 (2009).
4. Thrall, G., Lane, D., Carroll, D. & Lip, G. Y. H. Quality of life in patients with atrial fibrillation: A systematic review. Am. J. Med. 119(448), e1-448.e19 (2006).
5. Andersson, T. et al. All-cause mortality in 272,186 patients hospitalized with incident atrial fibrillation 1995–2008: A Swedish nationwide long-term case-control study. Eur. Heart J. 34, 1061–1067 (2013).